Evidence map›Paper›PMID 40283954›Full record

ReviewPharmaceuticals (Basel, Switzerland)2025

Mechanisms of Action of AGuIX as a Pan-Cancer Nano-Radiosensitizer: A Comprehensive Review.

Clémentine Aubrun, Tristan Doussineau, Léna Carmès, Aurélien Meyzaud, Fabien Boux, Sandrine Dufort, Adeline Delfour, Olivier De Beaumont, Céline Mirjolet, Géraldine Le Duc

Abstract readReview
In one paragraph

Review in Pharmaceuticals (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Lanthanide Nanotheranostics in Radiotherapy.International journal of molecular sciences · 2025
    Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Clémentine AubrunNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.ORCID 0000-0001-8520-1677
Tristan DoussineauNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Léna CarmèsNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Aurélien MeyzaudNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Fabien BouxNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.ORCID 0000-0002-3417-1313
Sandrine DufortNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Adeline DelfourNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Olivier De BeaumontNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.
Céline MirjoletX-Rain: Research Unit in Radiotherapy Combined with Immunotherapies and Nanoparticles, IMATHERA, Radiation Therapy Department, Centre Georges-François Leclerc, 21000 Dijon, France.ORCID 0000-0003-0047-9421
Géraldine Le DucNH TherAguix SA, 19 Chemin des Prés, 38240 Meylan, France.ORCID 0000-0003-2724-6847

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

enhanced permeability and retention (EPR)ferroptosisimmune responsenanomedicinenanoparticleradiobiologyradioenhancementradiosensitizerradiotherapytheranostic

Identifiers

PMID40283954
PMCPMC12030438

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.